Fujirebio Submits FDA Regulatory Filing for Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test
September 26, 2024,TOKYO, Japan & MALVERN, Pa., United States : Fujirebio today announced that its wholly-owned subsidiary Fujirebio Diagnostics, Inc. has filed its Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test with the U.S. Food and Drug Administration (FDA). The new plasma test is expected to be the first commercially available blood-based …